Sanofi and partner Orano Med reported positive Phase 2 results for AlphaMedix, a targeted alpha‑emitting radiopharmaceutical in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). In a 61‑patient study, AlphaMedix met primary endpoints for overall response rate with a manageable safety profile across cohorts who had and had not previously received Lutathera, the beta‑emitter standard. Sanofi, which licensed the 212Pb‑based program after a multi‑hundred‑million‑dollar deal with RadioMedix and Orano Med, said the findings will form the basis for regulatory discussions. Orano Med highlighted the Phase 2 data as validation of its lead platform for targeted alpha therapy. The companies withheld full datasets pending presentation at a medical meeting but flagged clinically meaningful activity and tolerability. The readout strengthens investor confidence in alpha emitters for solid tumors and may accelerate global development plans and pivotal study design discussions with regulators.